Japan Cracks Down on CBN: The End of a Cannabis ‘Gray Area’

Japan is once again tightening its stance on cannabis-derived compounds. This time, the focus is on cannabinol (CBN), a cannabinoid less well-known than THC or CBD, but one that is increasingly found in products aimed at relaxation and sleep support. The decision, reported by International CBC, marks a new chapter in the Asian country’s regulation, which has been combining limited medical access with strict punitive policies.

To understand the measure, we must first look at the context. Cannabis contains dozens of cannabinoids: the best-known are THC and CBD, but in recent years the market has begun exploring “secondary” compounds such as CBN, which is primarily associated with sleep aids.

In Japan, where THC remains strictly prohibited, these derivatives fell into a legal gray area. Since they were not explicitly regulated, they started being sold in various formats, such as edibles, oils, tinctures, vaep products, and functional snacks.

This growth was no accident. Globally, “non-traditional” cannabinoids have been gaining ground as alternatives in restricted markets, taking advantage of legal loopholes.

That loophole has just been closed. Japan’s Ministry of Health has classified CBN as a “designated drug,” effectively banning it almost entirely.

As reported by The Japan Times, Japan’s Ministry of Health announced on Wednesday that it has classified cannabinol as a “controlled substance,” banning its production, import, sale, and consumption as of June 1, except for limited medical purposes. This means that, as of that date, all commercial and consumer activity involving CBN will be prohibited, with very limited exceptions.

The measure directly impacts a market that had grown significantly in both brick-and-mortar and online stores. As the same publication details: “Under the revised ordinance, CBN products—which are sold on the domestic market both in physical stores and online in the form of gummies, cookies, oils, and e-cigarettes—will effectively disappear from the consumer market.”

The regulation affects not only companies, but also current users. The Japanese government has clearly outlined the deadlines and conditions.

On the one hand, a very limited medical exception has been introduced: use will only be permitted for patients with specific conditions, such as incurable diseases for which no alternative treatment exists.

On the other hand, those who currently possess CBN products must dispose of them before the deadline: “Consumers who currently have any product containing CBN in their possession must dispose of them before June 1, according to the ministry,” International CBC reported.

The decision did not come out of nowhere. In December 2023, Japan passed a reform authorizing certain cannabis-derived medicinal products under strict conditions, while strengthening penalties for unauthorized use.

However, that legislation did not cover all existing cannabinoids. This created a “gray area” that allowed for the circulation of hemp-derived compounds, such as CBN.

Now, with this new classification, the government seeks to close that loophole.

Key points about the legal context:

What is happening in Japan is not an isolated case. As the global cannabis market evolves, regulators face a constant challenge: keeping up with compounds that emerge faster than they can be regulated.

Cannabinoids such as CBN, CBG, or synthetic variants of THC have been at the forefront of this new phase, often serving as legal alternatives in restrictive markets, but that same dynamic often leads to bans once they gain visibility.